Table of Content

1 INTRODUCTION (Page No. - 26)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED
    1.5 RESEARCH LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 30)
    2.1 RESEARCH DATA
           2.1.1 SECONDARY SOURCES
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
    2.2 MARKET SIZE ESTIMATION
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    2.4 MARKET SHARE ESTIMATION
    2.5 STUDY ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. - 39)

4 PREMIUM INSIGHTS (Page No. - 44)
    4.1 ACTIVE PHARMACEUTICAL INGREDIENT MARKET OVERVIEW
    4.2 GLOBAL MARKET, BY TYPE
    4.3 GLOBAL MARKET, BY POTENCY
    4.4 GLOBAL MARKET, BY TYPE  OF SYNTHESIS
    4.5 GLOBAL MARKET, BY TYPE  OF DRUG
    4.6 GEOGRAPHIC SNAPSHOT: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

5 MARKET OVERVIEW (Page No. - 48)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 Growing importance of generics
                    5.2.1.2 Increasing uptake of biopharmaceuticals
                    5.2.1.3 Growing focus on precision medicine
                    5.2.1.4 Technological advancements in API manufacturing
                    5.2.1.5 Increasing incidence of chronic diseases
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable drug price control policies across various countries
                    5.2.2.2 High manufacturing cost
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging biosimilars market
                    5.2.3.2 Highly potent active pharmaceutical ingredients
                    5.2.3.3 Emerging markets
                    5.2.3.4 Emerging technologies
           5.2.4 CHALLENGES
                    5.2.4.1 Increasing penetration of counterfeit drugs
    5.3 VALUE CHAIN ANALYSIS
    5.4 SUPPLY CHAIN ANALYSIS
    5.5 ECOSYSTEM ANALYSIS
    5.6 PATENT ANALYSIS
    5.7 KEY CONFERENCES AND EVENTS
    5.8 TARIFF AND REGULATORY LANDSCAPE
    5.9 PORTER’S FIVE FORCES ANALYSIS
    5.10 KEY STAKEHOLDERS IN BUYING PROCESS
    5.11 INDICATIVE PRICING ANALYSIS
    5.12 TRADE ANALYSIS

6 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE (Page No. - 59)
    6.1 INTRODUCTION
    6.2 GLOBAL MARKET, BY TYPE (CAPTIVE AND MERCHANT)
    6.3 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS
           6.3.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES TO HAVE REGULATORY APPROVAL DRIVE MARKET
    6.4 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS
           6.4.1 GOVERNMENT INITIATIVES SUPPORTING GENERIC DRUGS ADOPTION TO BOOST MARKET

7 ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY POTENCY (Page No. - 64)
    7.1 INTRODUCTION
    7.2 GLOBAL MARKET, BY POTENCY (CAPTIVE AND MERCHANT)
    7.3 TRADITIONAL API 
           7.3.1 PROPERTIES OF TRADITIONAL APIS LIKE, HEIGHTENED POTENCY, QUICK ABSORPTION RATES, AND HAVE A SUSPECTED OR KNOWN GENIC EFFECT TO DRIVE MARKET GROWTH
    7.4 HPAPI
           7.4.1 HPAPIS INCREASING APPLICATIONS ACROSS A RANGE OF THERAPEUTIC AREAS ARE DRIVING THE MARKET GROWTH

8 ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY TYPE OF SYNTHESIS (Page No. - 74)
    8.1 INTRODUCTION
    8.2 GLOBAL MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT)
    8.3 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS
           8.3.1 SYNTHETIC APIs MARKET,  BY TYPE
                    8.3.1.1 Innovative synthetic APIs
                               8.3.1.1.1 High value of innovative APIs to drive segment
                    8.3.1.2 Generic synthetic APIs
                               8.3.1.2.1 Initiatives for penetration of generics to bring down healthcare costs
    8.4 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS
           8.4.1 BIOTECH APIs MARKET, BY TYPE
                    8.4.1.1 Innovative biotech APIs
                               8.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive segment
                    8.4.1.2 Generic biotech APIs
                               8.4.1.2.1 Increasing demand for biosimilar drugs due to their cost-effectiveness to drive segment
           8.5.2 BIOTECH APIs MARKET,  BY PRODUCT
                    8.5.2.1 Monoclonal antibodies
                               8.5.2.1.1 Growing applications of antibody-drug conjugates in cancer treatment to drive segment
                    8.5.2.2 Hormones & growth factors
                               8.5.2.2.1 Growing incidence of hormonal disorders to boost segment
                    8.5.2.3 Cytokines
                               8.5.2.3.1 Interferons and interleukins boost immune system and have important applications in cancer treatment
                    8.5.2.4 Fusion proteins
                               8.5.2.4.1 Growing applications of fusion proteins in biopharmaceuticals to drive segment
                    8.5.2.5 Recombinant vaccines
                               8.5.2.5.1 Growing prevalence of infectious diseases to boost vaccine development
                    8.5.2.6 Therapeutic enzymes
                               8.5.2.6.1 Growing significance of enzymes in therapies for cancer and pain management to drive segment
                    8.5.2.7 Blood factors
                               8.5.2.7.1 Growing incidence of hemophilia to drive the growth of this segment
           8.6.3 BIOTECH APIs MARKET,  BY EXPRESSION SYSTEM
                    8.6.3.1 Mammalian expression systems
                               8.6.3.1.1 Ability of these systems to carry post-translational modification to drive segment
                    8.6.3.2 Microbial expression systems
                               8.6.3.2.1 Ability to provide high expression levels of proteins to drive segment
                    8.6.3.3 Yeast expression systems
                               8.6.3.3.1 Advantages such as efficient protein secretion, simple purification, and endotoxin-free products to boost demand
                    8.6.3.4 Insect expression systems
                               8.6.3.4.1 Efficient post-translational modifications provided by these systems to boost demand
                    8.6.3.5 Other expression systems

9 ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY TYPE OF DRUG (Page No. - 96)
    9.1 INTRODUCTION
    9.2 GLOBAL MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT)
    9.3 PRESCRIPTION DRUGS
           9.3.1 GROWING DISEASE PREVALENCE TO DRIVE MARKET
    9.4 OVER-THE-COUNTER DRUGS
           9.4.1 SALES OF OTC DRUGS TO RISE DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS

10 ACTIVE PHARMACEUTICAL INGREDIENT MARKET,  BY THERAPEUTIC APPLICATION (Page No. - 103)
     10.1 INTRODUCTION
     10.2 GLOBAL MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT)
     10.3 COMMUNICABLE DISEASES
             10.3.1 GLOBAL HEALTH IMPACT OF COMMUNICABLE DISEASES AND INCREASING ANTIMICROBIAL RESISTANCE TO AID MARKET
     10.4 ONCOLOGY
             10.4.1 INCREASE IN GLOBAL SPENDING ON CANCER MEDICATION TO AUGMENT GROWTH
     10.5 PAIN MANAGEMENT
             10.5.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO DRIVE MARKET
     10.6 CARDIOVASCULAR DISEASES
             10.6.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES TO AID MARKET
     10.7 DIABETES
             10.7.1 HIGH GLOBAL PREVALENCE OF DIABETES TO DRIVE SEGMENT
     10.8 RESPIRATORY DISEASES
             10.8.1 HIGH GLOBAL PREVALENCE OF RESPIRATORY DISEASES TO PROPEL GROWTH
     10.9 OTHER THERAPEUTIC APPLICATIONS

11 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION (Page No. - 113)
     11.1 INTRODUCTION
     11.2 GLOBAL MARKET, BY REGION (CAPTIVE AND MERCHANT)
     11.3 NORTH AMERICA
             11.3.1 US
                        11.3.1.1 Increasing expenditure on medicine to drive market
             11.3.2 CANADA
                        11.3.2.1 Support from government organizations to propel growth
     11.4 EUROPE
             11.4.1 GERMANY
                        11.4.1.1 Germany to dominate European market in 2021
             11.4.2 FRANCE
                        11.4.2.1 Emergence of pharmerging markets in Asia to hinder growth
             11.4.3 UK
                        11.4.3.1 Growing adoption of generics to drive market
             11.4.4 ITALY
                        11.4.4.1 Italy’s share in merchant APIs market to remain stable during forecast period
             11.4.5 SPAIN
                        11.4.5.1 Spanish market to be dominated by branded drugs
             11.4.6 REST OF EUROPE
     11.5 ASIA PACIFIC
             11.5.1 JAPAN
                        11.5.1.1 Japanese government to boost use of generics by 2020
             11.5.2 CHINA
                        11.5.2.1 Government policies to increase medicine access and affordability
             11.5.3 INDIA
                        11.5.3.1 India to be leading producer of generics
             11.5.4 SOUTH KOREA
                        11.5.4.1 Government initiatives to introduce full medical coverage for major chronic diseases
             11.5.5 REST OF ASIA
     11.6 REST OF THE WORLD

12 COMPETITIVE LANDSCAPE (Page No. - 200)
     12.1 OVERVIEW
     12.2 KEY PLAYER STRATEGIES/ RIGHT TO WIN
     12.3 MARKET SHARE ANALYSIS
     12.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
     12.5 COMPETITIVE EVALUATION QUADRANT
             12.3.1 STARS
             12.3.2 EMERGING LEADERS
             12.3.3 PERVASIVE PLAYERS
             12.3.4 PARTICIPANTS
     12.4 COMPANY EVALUATION QUADRANT
             12.4.1 PROGRESSIVE COMPANIES
             12.4.2 STARTING BLOCKS
             12.4.3 RESPONSIVE COMPANIES
             12.4.4 DYNAMIC COMPANIES
     12.4 REGIONAL FOOTPRINT OF COMPANIES
     12.5 COMPETITIVE SCENARIO

13 COMPANY PROFILES (Page No. - 209)
(Business overview, Products offered, Recent Developments, MNM view)*
     13.1 PFIZER, INC.
     13.2 NOVARTIS AG
     13.3 SANOFI
     13.4 BOEHRINGER INGELHEIM
     13.5 BRISTOL-MYERS SQUIBB
     13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
     13.7 ELI LILLY AND COMPANY
     13.8 GLAXOSMITHKLINE PLC
     13.9 MERCK & CO., INC.
     13.10 ABBVIE INC.
     13.11 F. HOFFMANN-LA ROCHE
     13.12 ASTRAZENECA
     13.13 MYLAN NV
     13.14 DR REDDY’S LABORATORIES LTD. 
     13.15 SUN PHARMACEUTICAL LTD.
     13.16 CIPLA INC.
     13.17 AUROBINDO PHARMA LTD.
     13.18 EVONIK INDUSTRIES AG
     13.19 API PHARMA TECH
     13.20 SREEPATHI PHARMACEUTICALS LTD.
     13.21 BDR PHARMACEUTICALS INTERNATIONAL LTD.
     13.22 SHILPA MEDICARE LTD.

14 APPENDIX (Page No. - 246)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 CUSTOMIZATION OPTIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS


LIST OF TABLES (180 TABLES)

TABLE 1 INDICATIVE LIST OF DRUGS GOING GENERIC IN 2021
TABLE 2 INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL  IN US IN 2019-2021
TABLE 3 INDICATIVE LIST OF BIOSIMILARS THAT GAINED US REGULATORY APPROVAL IN 2021
TABLE 4 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 5 INDICATIVE LIST OF NEW MOLECULAR ENTITIES THAT GAINED US FDA APPROVAL IN 2021
TABLE 6 LIST OF MAJOR DRUGS SET TO LOSE PATENT PROTECTION IN 2021
TABLE 7 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION,  2022–2027 (USD BILLION)
TABLE 8 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2022–2027 (USD BILLION)
TABLE 9 GLOBAL APIs MARKET, BY TYPE OF SYNTHESIS, 2022–2027 (USD BILLION)
TABLE 10 SYNTHETIC APIs MARKET, BY REGION, 2022–2027 (USD BILLION)
TABLE 11 SYNTHETIC APIs MARKET, BY TYPE  2022–2027 (USD BILLION)
TABLE 12 INNOVATIVE SYNTHETIC APIs MARKET, BY REGION, 2022–2027 (USD BILLION)
TABLE 13 GENERIC SYNTHETIC APIs MARKET, BY REGION, 2022–2027 (USD BILLION)
TABLE 14 TOP SELLING BIOLOGICS (2021)
TABLE 15 BIOTECH APIs MARKET, BY REGION, 2022–2027 (USD BILLION)
TABLE 16 BIOTECH APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 17 INNOVATIVE BIOTECH APIs MARKET, BY REGION, 2022–2027 (USD BILLION)
TABLE 18 INDICATIVE LIST OF BIOSIMILARS THAT GAINED US FDA APPROVAL DURING 2017–2018
TABLE 19 GENERIC BIOTECH APIs MARKET, BY REGION, 2022–2027 (USD BILLION)
TABLE 20 BIOTECH APIs MARKET, BY PRODUCT 2022–2027 (USD BILLION)
TABLE 21 INDICATIVE LIST OF MONOCLONAL ANTIBODIES THAT RECEIVED FDA APPROVAL IN 2018
TABLE 22 BIOTECH APIs MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022–2027 (USD BILLION)
TABLE 23 BIOTECH APIs MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2022–2027 (USD BILLION)
TABLE 24 BIOTECH APIs MARKET FOR CYTOKINES, BY REGION, 2022–2027 (USD BILLION)
TABLE 25 BIOTECH APIs MARKET FOR FUSION PROTEINS,  BY REGION, 2022–2027 (USD BILLION)
TABLE 26 BIOTECH APIs MARKET FOR RECOMBINANT VACCINES, BY REGION, 2022–2027 (USD MILLION)
TABLE 27 BIOTECH APIs MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2022–2027 (USD MILLION)
TABLE 28 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BLOOD FACTORS,  BY REGION, 2022–2027 (USD MILLION)
TABLE 29 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2022–2027 (USD BILLION)
TABLE 30 BIOTECH APIs MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2022–2027 (USD BILLION)
TABLE 31 BIOTECH APIs MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2022–2027 (USD BILLION)
TABLE 32 BIOTECH APIs MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2022–2027 (USD BILLION)
TABLE 33 BIOTECH APIs MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2022–2027 (USD BILLION)
TABLE 34 BIOTECH APIs MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2022–2027 (USD MILLION)
TABLE 35 GLOBAL MARKET, BY TYPE OF DRUG, 2022–2027 (USD BILLION)
TABLE 36 PRESCRIPTION DRUGS MARKET, BY REGION, 2022–2027 (USD BILLION)
TABLE 37 OVER-THE-COUNTER DRUGS MARKET, BY REGION, 2017-2024 (USD BILLION)
TABLE 38 GLOBAL MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 39 GLOBAL MARKET, BY THERAPEUTIC APPLICATION,  2022–2027 (USD BILLION)
TABLE 40 INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR COMMUNICABLE DISEASES (2021)
TABLE 41 GLOBAL MARKET FOR COMMUNICABLE DISEASES,  BY REGION, 2022–2027 (USD BILLION)
TABLE 42 INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR ONCOLOGY (2021)
TABLE 43 GLOBAL MARKET FOR ONCOLOGY, BY REGION, 2022–2027 (USD BILLION)
TABLE 44 INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR PAIN MANAGEMENT (2021)
TABLE 45 GLOBAL MARKET FOR PAIN MANAGEMENT, BY REGION, 2022–2027 (USD BILLION)
TABLE 46 GLOBAL MARKET FOR CARDIOVASCULAR DISEASES,  BY REGION, 2022–2027 (USD BILLION)
TABLE 47 GLOBAL MARKET FOR DIABETES, BY REGION,  2022–2027 (USD BILLION)
TABLE 48 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES,  BY REGION, 2022–2027 (USD BILLION)
TABLE 49 GLOBAL APIs MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2022–2027 (USD BILLION)
TABLE 50 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION, 2022–2027 (USD BILLION)
TABLE 51 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2022–2027 (USD BILLION)
TABLE 52 NORTH AMERICA: APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 53 NORTH AMERICA: APIs MARKET, BY TYPE OF SYNTHESIS, 2022–2027 (USD BILLION)
TABLE 54 NORTH AMERICA: SYNTHETIC APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 55 NORTH AMERICA: BIOTECH APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 56 NORTH AMERICA: BIOTECH APIs MARKET, BY PRODUCT, 2022–2027 (USD BILLION)
TABLE 57 NORTH AMERICA: APIs MARKET, BY TYPE OF DRUG, 2022–2027 (USD BILLION)
TABLE 58 NORTH AMERICA: APIs MARKET, BY POTENCY,  2022–2027 (USD BILLION)
TABLE 59 NORTH AMERICA: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 60 INDICATIVE LIST OF RECENT FDA APPROVALS FOR DRUG DELIVERY PRODUCTS
TABLE 61 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 62 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 63 US: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 64 US: BIOTECH APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 65 US: APIs MARKET, BY TYPE OF DRUG, 2022–2027 (USD BILLION)
TABLE 66 US: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 67 US: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 68 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 69 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF SYNTHESIS, 2022–2027 (USD BILLION)
TABLE 70 CANADA: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 71 CANADA: BIOTECH APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 72 CANADA: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 73 CANADA: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 74 CANADA: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 75 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022–2027 (USD BILLION)
TABLE 76 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 77 EUROPE: APIs MARKET, BY TYPE OF SYNTHESIS, 2022–2027 (USD BILLION)
TABLE 78 EUROPE: SYNTHETIC APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 79 EUROPE: BIOTECH APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 80 EUROPE: BIOTECH APIs MARKET, BY PRODUCT, 2022–2027 (USD BILLION)
TABLE 81 EUROPE: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 82 EUROPE: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 83 EUROPE: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 84 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 85 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2022–2027 (USD BILLION)
TABLE 86 GERMANY: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 87 GERMANY: BIOTECH APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 88 GERMANY: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 89 GERMANY: APIs MARKET, BY POTENCY,  2022–2027 (USD BILLION)
TABLE 90 GERMANY: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 91 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 92 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2022–2027 (USD BILLION)
TABLE 93 FRANCE: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 94 FRANCE: BIOTECH APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 95 FRANCE: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 96 FRANCE: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 97 FRANCE: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 98 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 99 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 100 UK: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 101 UK: BIOTECH APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 102 UK: APIs MARKET, BY TYPE OF DRUG, 2022–2027 (USD BILLION)
TABLE 103 UK: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 104 UK: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 105 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 106 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 107 ITALY: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 108 ITALY: BIOTECH APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 109 ITALY: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 110 ITALY: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 111 ITALY: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 112 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 113 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 114 SPAIN: SYNTHETIC APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 115 SPAIN: BIOTECH APIs MARKET, BY TYPE,  2022–2027 (USD MILLION)
TABLE 116 SPAIN: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 117 SPAIN: APIs MARKET, BY POTENCY, 2022–2027 (USD MILLION)
TABLE 118 SPAIN: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD MILLION)
TABLE 119 REST OF EUROPE: APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 120 REST OF EUROPE: APIs MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 121 REST OF EUROPE: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 122 REST OF EUROPE: BIOTECH APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 123 REST OF EUROPE: APIs MARKET, BY TYPE OF DRUG, 2022–2027 (USD BILLION)
TABLE 124 REST OF EUROPE: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 125 REST OF EUROPE: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 126 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022–2027 (USD BILLION)
TABLE 127 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 128 ASIA PACIFIC: APIs MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 129 ASIA PACIFIC: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 130 ASIA PACIFIC: BIOTECH APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 131 ASIA PACIFIC: BIOTECH APIs MARKET, BY PRODUCT,  2022–2027 (USD MILLION)
TABLE 132 ASIA PACIFIC: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 133 ASIA PACIFIC: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 134 ASIA PACIFIC: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 135 JAPAN: APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 136 JAPAN: APIs MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 137 JAPAN: SYNTHETIC APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 138 JAPAN: BIOTECH APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 139 JAPAN: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 140 JAPAN: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 141 JAPAN: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 142 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 143 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 144 CHINA: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 145 CHINA: BIOTECH APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 146 CHINA: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 147 CHINA: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 148 CHINA: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 149 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 150 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 151 INDIA: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 152 INDIA: BIOTECH APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 153 INDIA: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 154 INDIA: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 155 INDIA: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 156 SOUTH KOREA: APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 157 SOUTH KOREA: APIs MARKET, BY TYPE OF SYNTHESIS, 2022–2027 (USD BILLION)
TABLE 158 SOUTH KOREA: SYNTHETIC APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 159 SOUTH KOREA: BIOTECH APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 160 SOUTH KOREA: APIs MARKET, BY TYPE OF DRUG, 2022–2027 (USD BILLION)
TABLE 161 SOUTH KOREA: APIs MARKET, BY POTENCY,  2022–2027 (USD BILLION)
TABLE 162 SOUTH KOREA: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 163 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 164 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 165 REST OF ASIA PACIFIC: SYNTHETIC APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 166 REST OF ASIA PACIFIC: BIOTECH APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 167 REST OF ASIA PACIFIC: APIs MARKET, BY TYPE OF DRUG, 2022–2027 (USD BILLION)
TABLE 168 REST OF ASIA PACIFIC: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 169 REST OF ASIA PACIFIC: APIs MARKET, BY THERAPEUTIC APPLICATION, 2022–2027 (USD BILLION)
TABLE 170 REST OF THE WORLD: APIs MARKET,  BY TYPE, 2022–2027 (USD BILLION)
TABLE 171 REST OF THE WORLD: APIs MARKET, BY TYPE OF SYNTHESIS,  2022–2027 (USD BILLION)
TABLE 172 REST OF THE WORLD: SYNTHETIC APIs MARKET, BY TYPE, 2022–2027 (USD BILLION)
TABLE 173 REST OF THE WORLD: BIOTECH APIs MARKET, BY TYPE,  2022–2027 (USD BILLION)
TABLE 174 REST OF THE WORLD: APIs MARKET, BY TYPE OF DRUG,  2022–2027 (USD BILLION)
TABLE 175 REST OF THE WORLD: APIs MARKET, BY POTENCY, 2022–2027 (USD BILLION)
TABLE 176 REST OF THE WORLD: APIs MARKET, BY THERAPEUTIC  APPLICATION, 2022–2027 (USD BILLION)
TABLE 177 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYER RANKING, 2018
TABLE 178 PRODUCT LAUNCHES, 2019–2021
TABLE 179 EXPANSIONS, 2019–2021
TABLE 180 ACQUISITIONS, 2019–2021


LIST OF FIGURES (36 FIGURES)

FIGURE 1 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: MARKET SEGMENTATION
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 4 BOTTOM-UP APPROACH
FIGURE 5 TOP-DOWN APPROACH
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,  2022 VS. 2027 (USD BILLION)
FIGURE 8 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF SYNTHESIS,  2022 VS. 2027
FIGURE 9 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT,  2022 VS. 2027
FIGURE 10 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022 VS. 2027
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
FIGURE 12 INCREASING INCIDENCE OF CHRONIC DISEASES AND GROWING IMPORTANCE OF GENERICS TO DRIVE MARKET
FIGURE 13 GENERIC APIS TO GROW AT HIGHEST CAGR FROM 2022 TO 2027
FIGURE 14 ONCOLOGY SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 15 PRESCRIPTION DRUGS TO COMMAND LARGEST MARKET SHARE IN 2019
FIGURE 16 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 17 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 18 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS SEGMENT TO DOMINATE MARKET IN 2021
FIGURE 19 SYNTHETIC APIS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 20 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUGS
FIGURE 21 NORTH AMERICA: MARKET SNAPSHOT
FIGURE 22 EUROPE: MARKET SNAPSHOT
FIGURE 23 EXPANSIONS—KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS
FIGURE 24 COMPETITIVE LEADERSHIP MAPPING
FIGURE 25 PFIZER, INC.: COMPANY SNAPSHOT (2021)
FIGURE 26 NOVARTIS AG: COMPANY SNAPSHOT (2021)
FIGURE 27 SANOFI: COMPANY SNAPSHOT (2021)
FIGURE 28 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2021)
FIGURE 29 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2021)
FIGURE 30 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
FIGURE 31 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2021)
FIGURE 32 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2021)
FIGURE 33 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
FIGURE 34 ABBVIE INC.: COMPANY SNAPSHOT (2021)
FIGURE 35 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
FIGURE 36 ASTRAZENECA: COMPANY SNAPSHOT (2021)